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Abstract
A graphite-polyurethane composite electrode has been used for the determination of furosemide, a antihypertensive
drug, in pharmaceutical samples by anodic oxidation. Cyclic voltammetry and electrochemical impedance
spectroscopy were used to characterize the electrooxidation process at þ1.0 V vs. SCE over a wide pH range, with
the result that no adsorption of analyte or products occurs, unlike at other carbon-based electrode materials.
Quantification was carried out using cyclic voltammetry, differential pulse voltammetry, and square-wave
voltammetry. Linear ranges were determined (up to 21 mmol L1 with cyclic voltammetry) as well as limits of
detection (0.15 mmol L1 by differential pulse voltammetry). Four different types of commercial samples were
successfully analyzed. Recovery tests were performed which agreed with those obtained by spectrophotometric
evaluation. The advantages of this electrode material for repetitive analyzes, due to the fact that no electrode surface
renewal is needed owing to the lack of adsorption, are highlighted.
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1. Introduction
Furosemide, also called frusemide (4-chloro-N-furfuryl-
sulfamoylantranilic acid) is a sulfonamide initially described
as an antibacterial agent but, due to its intense and fast
diuretic effect, also became used as an antihypertensive
drug, being currently sold in the form of tablets and as
parenteral solutions [1, 2]. The structure of the neutral form
of furosemide is shown in Figure 1; the protonated form has
four ionizable acid groups [3, 4]. It is soluble in alkaline
media, as well as in organic solvents such as acetone and
methanol; however, it has a very low solubility in water and
acidic aqueous solutions [2].
A wide range of reports has been published concerning
the determination of this analyte and/or its products, after
reactions such as hydrolysis, oxidation, complexation, or
diazotization, in commercial samples and in biological
matrices. Chromatographic separation has been followed
by detection methods such as UV-vis spectrophotometry
[5 – 7], or amperometric detection at glassy carbon [8] or
carbon fiber microelectrodes [9]. Additionally, optical
methods based on absorption or emission [10 – 40], direct
electrochemical [41, 42], and titrimetric procedures [43 – 45]
have also been used, with a clear predominance of
spectrophotometric compared to electrochemical methods.
Reviews presenting the Fstate of the artG for furosemide
determination [46 – 48], reported lowest limits of detection
of 3 1010 mol L1 usingHPLC-MSand 2.1 108 mol L1,
employing micellar liquid chromatography with a diode
array detector.
A comparison between the analytical parameters ob-
tainedby various electrochemical procedures is presented in
Table 1. A limit of detection close to 1.5 107 mol L1 is
found at glassy carbon electrodes, but with the necessity of
renewal of the electrode surface after eachmeasurement, in
order to achieve reproducible responses [41]; limits of
detection of 1.7 107 mol L1 (using flow injection analy-
sis) and 5.5 107 mol L1 using HPLC with electrochem-
ical detection were found in [8] at glassy carbon electrodes.
In the latter case, the oxidation peak potential had a
relatively high value, close to þ1.25 V vs. Ag/AgCl (1 M
KCl), electrode surface pre-treatment being needed before
eachmeasurement. For electrochemical determinations, the
main problemwhich causesmost difficulties is adsorption of
the analyte or its reaction products on the electrode surface.
Apart from solid carbon electrodes, such as glassy carbon,
composite electrodes have also been investigated for use in
oxidative electroanalytical procedures. The first description
of carbon paste composites, byAdams, dates from 1958 [49],
when new composite materials began to be evaluated in
order to substitute mercury and extend the use of electro-
chemical techniques to potential ranges where mercury is
not useable. A composite was defined by Tallman and
Petersen [50] as a mixture of components, each with
different properties, leading to a new material with new
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properties. Among the components it is necessary to have at
least one insulator and one conductor.
This work reports the use of a composite electrode with
graphite as conducting phase in a castor-oil polyurethane
resin of vegetable origin as insulating phase for the analysis
of furosemide in pharmaceutical samples. This graphite-
polyurethane composite began to be studied in 2002 [51], in
which the best conditions of preparation, cure and use were
described. Analytical applications to the determination of
hydroquinone in photographic developers [52], of imipr-
amine [53] and atenolol [54] in pharmaceutical formula-
tions, of dopamine in synthetic cerebrospinal fluid [55] and
of indoleacetic acid in the environment [56] have been
demonstrated. Advantages of such composites are the
possibility of manufacture in different shapes and sizes,
the easy addition of chemical modifiers to the composite,
applicability over a wide range of pH and in different
solvents, and low cost of production.
The application of this composite as an electrodematerial
in the analysis of furosemide, without problems of adsorp-
tion of furosemide itself or of its oxidation products, is
demonstrated.
2. Experimental
2.1. Reagents and Solutions
All reagents were of analytical grade and were used as
received; solutions were prepared by direct dissolution of
the salts in Millipore Milli-Q ultrapure water (resistivity
>18 MW cm).A1.00 mmolL1 stock solutionof furosemide
was prepared in 1.0 mmol L1 NaOH, and was diluted as
necessary on the day of use.
Commercial tablets, containing a nominal amount of
40 mg of furosemide per tablet, were purchased in Brazil
(Furosix, Neosemid, Pharlab, and Teuto). Twenty tablets
were triturated, according to the procedure outlined in the
United States Pharmacopeia [57, 58] until a fine and
homogeneous powder was obtained, from which chosen,
weighed amounts were taken and dissolved in 1.0 mmol L1
NaOH solution to give a final concentration of ca. 1 mmol
L1 furosemide. No previous separation or preparation step
was needed.
Buffer solutions (pH from 1.2 to 13.0) were prepared
according to Table 2 for characterizing the electrooxidation
process at different pH values and for evaluating the best
conditions for the analytical determination of furosemide.
2.2. Composite Electrode Preparation
Polyurethane resin was prepared by mixing 0.85 parts of
prepolymer A-249 and 1.0 part of polyol B-471 (Poliquil,
Fig. 1. Structure of the neutral form of furosemide.
Table 1. Electroanalytical procedures for determination of furosemide in the literature.
Detection Media LOD (mol dm3) Comments References
Amperometric detection at
a glassy carbon electrode
(þ1.3 V vs. Ag/AgCl) coupled
to HPLC
Water-acetonitrile (30 : 70) 4.5 108 Liquid-liquid extraction
needed (ethyl acetate).
[8]
Amperometric detection at carbon
fiber microelectrodes
(þ1.25 V vs. Ag/AgCl) coupled
to HPLC and FIA
Acetonitrile-water (25 : 75) with
5 mmol L1 NaH2PO4 (HPLC), and
5 mmol L1 NaH2PO4 pH 6.5 (FIA)
5.5 107 (HPLC),
1.7 107 (FIA)
Surface fouling,
electrochemical
treatment needed
after each measurement
[9]
Voltammetric detection at glassy
carbon electrodes
(þ1.2 V vs. Ag/AgCl)
Methanol-water (10 : 90) 1.5 107 Surface fouling,
surface renewal by
polishing followed by
methanol and water,
liquid-liquid extraction
needed (ethyl acetate).
[41]
Table 2. Buffer supporting electrolyte solutions, final concentra-
tion 0.1 mol dm3, made from component solutions of concentra-
tion 0.2 mol dm3 with dilution by a factor of two.
Composition pH
HClþKCl 1.2
HClþKCl 2.0
HOAcþNaOAc 3.3
HOAcþNaOAc 4.0
HOAcþNaOAc 5.3
Na2HPO4þNaH2PO4 5.8
Na2HPO4þNaH2PO4 6.9
Na2HPO4þNaH2PO4 8.0
Na2B4O7.10H2OþNaOH 9.3
NaOHþKCl 12.2
NaOHþKCl 13.0
2288 F. S. Semaan et al.
Electroanalysis 20, 2008, No. 21, 2287 – 2293 www.electroanalysis.wiley-vch.de L 2008 WILEY-VCH Verlag GmbH&Co. KGaA, Weinheim
Brazil). Suitable amounts of graphite powder, 1 – 2 mm
diameter (Aldrich, USA) were added in order to reach 60%
in mass. This mixture was homogenized in a mortar during
15 minutes and then extruded as 3.0 mm diameter rods [50].
The rods were left to cure during 24 hours and then cut into
1 cm sections. Contacts were made using silver epoxy glue
and copper wire, and the assembly was sealed in non-
conducting epoxide resin. The surfaces were polished using
abrasive paper followed by a-Al2O3 of 1.0 mm diameter
(Arotec, Brazil).
The electroactive surface area was determined by cyclic
voltammetry, using 5 mmol L1 hexacyanoferrate(II) in
0.5 mol L1 KCl and different potential scan rates (10 –
75 mV s1): and applying Equation 1:
Ipa (A)¼ 2.95 105 n3/2 A D1/2 c1 v1/2 (1)
where n is number of electrons involved in the oxidation,A
is the electroactive area (cm2),D is the diffusion coefficient
of hexacyanoferrate(II) in cm2 s1 (7.7 106 cm2 s1 in
0.5 mol L1 KCl [59]), c1 the bulk concentration of
hexacyanoferrate(II) in mol cm3, and v the potential scan
rate, in V s1. From a plot of peak current vs. scan rate the
electroactive area was found to be ca. 0.043 cm2, corre-
sponding to 61% of the geometric area.
2.3. Apparatus
Voltammetric experiments were carried out with a com-
puter-controlledm-AutolabType II potentiostat/galvanostat
with GPES 4.9 software (Eco Chemie, Netherlands). A
three-electrode cell, with 20 mL capacity, was used; the
reference electrode was a saturated calomel electrode
(SCE) and the counter electrode was platinum foil (area
1 cm2).
Electrochemical impedance measurements were carried
out in the same electrochemical cell with a PC-controlled
Solartron 1250 Frequency Response Analyzer coupled to a
Solartron 1286 Electrochemical Interface using ZPlot 2.4
software (Solartron Analytical, UK), frequency scans were
from 65000 Hz down to 0.1 Hz with ten measurements per
frequency decade, using a sinusoidal voltage perturbation of
10 mV rms. For comparative studies by UV-visible spectro-
photometry, a Specord S100 Carl Zeiss spectrophotometer
was used, at a wavelength of 271 nm. All measurements
were carried out at room temperature (25 1 8C) without
deaeration of solutions.
2.4. Procedures
Cyclic voltammetry was carried out in different buffer
solutions of pH between 1.2 and 13.0, from 1.0 to þ1.2 V
(vs. SCE). Five sequential cycles were recorded and the
difference in response between blank and spiked solutions
(6.5 105 mol L1) was measured.
Quantificationwas carried out by cyclic, differential pulse
and square-wave voltammetry. In cyclic voltammetry, scan
rates from 10 to 100 mV s1 were tested. For DPV, an
effective scan rate of 10 mV s1 (10 mV scan increment) was
applied for amplitude modulation optimization (10, 25, 50,
and 100 mV), then the optimum amplitude was fixed in
order to find the best apparent scan rate (10, 25, 50, and
100 mV s1). In the case of SWV, the frequency (10, 25, 50
and 100 Hz), and step potential (1, 2, and 5 mV) were both
varied as well as the amplitude (10 to 50 mV).
Electrochemical impedance spectroscopy studies were
done in order to evaluate the electrode process and the
occurrence of any adsorption phenomena, first atþ1.0 V vs.
SCE, for blank and spiked solutions (0.12 mmol L1,
pH 3.3). Spectra were then also recorded at different
furosemide concentrations (8 and 16 mmol L1) and poten-
tials (þ0.5, þ0.75, þ1.0, and þ1.1 V vs. SCE).
2.5. Spectrophotometric Reference Procedure
The samples were analyzed by UV-vis spectrophotometry,
and compared with a solution of known concentration using
NaOH as extractor solution, with detection at 271 nm. The
details of this procedure are described in the United States
Pharmacopoeia [57]. Although the most recent USA
Pharmacopoeia suggests the use of HPLC procedures [58],
in the present case the UV-vis procedure was chosen due to
its simplicity and low waste generation.
3. Results and Discussion
3.1. Influence of pH and Mechanistic Studies
Cyclic voltammetry experiments were carried out in differ-
ent buffer solutions from pH 1.2 to 13.0 in order to choose
the most suitable value of pH for the electroanalytical
measurements. The best definition of signals was in pH 3.3
acetate buffer solution, with an oxidation peak atþ1.0 V vs.
SCE at pH 3.3 (see Fig. 2). Figure 3a shows the relationship
between pH and peak potential, up to pH 6 (above this pH
no signal was obtained), with slope close to 30 mV up to
pH 4 which suggests the involvement of two electrons for
each proton in the electrochemical oxidation of furosemide.
The relationship between log Ipa and log scan rate with slope
close to 0.5 shows a diffusion-controlledmechanism,with no
adsorption (see Fig. 3b).
The oxidation was also studied by differential pulse
voltammetry and square-wave voltammetry. The oxidation
peak half-width, W1/2, is close to 70 mV, suggesting a two-
electron irreversible process, confirmed by the fact that the
SWVbackward component current shows no cathodic peak
(data not shown). These results are in agreement with those
from cyclic voltammetry here and in [41], where values for
an were shown to be in agreement with two-electron
processes.
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In order to propose a possible electrooxidation mecha-
nism, it is necessary to consider the different species which
exist as a function of pH. The determination of the pKa of a
substance with multiple deprotonation steps and low
solubility is not easy to perform [3]. Values have been given
for deprotonation involving the successive reactions:
H3A
þÐ
pK1
H2AÐ
pK2
HAÐ
pK3
A2Ð
pK4
A3
related to the protonated nitrogen at position 6, the
carboxylic group, a second proton from the nitrogen at
position 6 and the sulfonamide group, respectively (see
Fig. 1 for the structure of the neutral form H2A).
Experimental values obtained by different techniques
estimate pK1 0.5 from octanol/water partition measure-
ments [3] and pK2¼ 3.9; 3.8; 3.65 or 3.6, determined by
aqueous solution titration;mixed solvents titration; octanol/
water partition and solubility methods respectively [3].
Using liquid chromatography a 3.9 value has been assigned
to the carboxylic acid dissociation [4].
These data confirm that in the pH range studied where a
signal is obtained, up to pH 6, the species occurring are the
neutral species shown in Figure 1 and that corresponding to
ionization of the carboxyl group. The potential at which
oxidation occurs suggests that it is of the amine at position 6,
which will initially give rise to a cation radical. In order to
explain the experimental observations (loss of 2 electrons
and one proton), this must then be immediately followed by
loss of a second electron and of a proton. The highly reactive
species which are produced, could dimerize and undergo
other reactions. It is extremely likely that the cation radical
undergoes a homogeneous reaction very quickly because
otherwise the effects of the following chemical reaction
would be seen in the cyclic voltammograms [60] and/or a
strong interaction with the electrode surface would occur,
leading to blocking adsorption, as occurred in [41, 42]. 3.2. Electrochemical Impedance Spectroscopy
Electrochemical impedance spectroscopy experiments
were done with the aim of evaluating the possibility of
analyte adsorption on the electrode surface. Impedance
spectra were recorded in blank solutions, as well as before
and after fifteen successive potential cycles in 0.12 mmolL1
furosemide – the electrode then being washed with water
without polishing, and replaced in the cell.
Impedance spectra, recorded at potentials lower and
higher than the oxidation peak (þ0.50, þ0.75 and þ1.10 V
vs. SCE), in the absence of furosemide and after cycling in
solutions spiked with 8 and 16 mmol L1 furosemide, are
shown inFigure 4.An equivalent electrical circuit with a cell
resistance, RW, in series with a parallel combination of a
Constant Phase Element, CPE, and a charge transfer
resistance was used to fit the curves. In all cases, the
CPE¼ {C (iw)a}1 models a nonideal capacitor. The CPE
was found to be necessary because of the heterogeneous
nature of the electrode, expressed through the exponent a.
A typical value of ca. 0.80 was obtained for all spectra,
independent of the presence of furosemide. The cell
Fig. 2. Cyclic voltammogram of 1.3 104 mol L1 furosemide in
pH 3.3 acetate buffer solution, scan rate 100 mV s1.
Fig. 3. a) Dependence of cyclic voltammetric peak current, Ip,
(*) and peak potential, Ep, (&) on pH for 1.3 104 mol L1
furosemide; scan rate (v) 100 mV s1. b) Plot of log Ip vs. log v for
6.5 105 mol L1 furosemide in pH 3.3 acetate buffer electrolyte.
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resistance RW was around 192W cm
2, a value expected for a
composite electrode.
At þ0.5 V, the general features of the spectra are similar
in the absence or presence of furosemide, and are charac-
terized by an inclined straight-line shape. The observed
effect can be considered as a non-ideal capacitor, due to the
intrinsic characteristic of the electrode material. At þ0.75
and þ1.0 V (vs. SCE), the same tendencies in the curves
were observed. Important information obtained, comparing
all spectra, is that the values of imaginary impedance (Z’’) do
not change significantlywith increasing potential, indicating
that the electrode surface has a well-defined behavior.
At þ1.1 V (vs. SCE), close to the positive limit of the
potential window, the spectra shape becomes similar to that
of a semicircle, with a corresponding decrease in R values.
At this potential, the capacitance values are more or less
constant. The reason is the beginning of solvent decom-
position.
Since no significant differences in the spectra were
observed after exposure to furosemide at any of these
potentials the conclusion is that there was no adsorption of
analyte or its oxidation products. The differences observed
in charge transfer are due only to the increase in the applied
potential.
3.3. Electroanalytical Procedures
Electroanalytical procedures were developed using cyclic,
differential pulse and square-wave voltammetry and the
results are presented in Table 3.
Using cyclic voltammetry at pH 3.3, , the electrode was
scanned at 100 mV s1 between 0 and þ1.2 V vs. SCE; for
blank, and three successive sample additions, see Figure 5.
A linear dependence of peak current on furosemide
concentration, was observed, illustrated for furosemide
from Neosemid, between 8 and 21 mmol L1 (Ip (A)¼
0.12 Cþ 3 106, R2¼ 0.9996, n¼ 5); limits of detection
and quantification were 2.8 and 8.4 mmol L1, respectively.
Recovery tests led to values between 96 and 101%.
Differential pulse voltammetry, Figure 6, was also used to
quantify the analyte. In this case, the best determination
conditions were found using an amplitude of 100 mV, and an
effective scan rate of 25 mV s1, scanning the potential from
þ0.5 to þ1.2 V (vs. SCE). A peak was observed at þ0.9 V.
The linear range was from 0.75 to 6.5 mmol L1 (Ip (A)¼
0.2 Cþ 1.5 106, R2¼ 0.998, n¼ 6, where C is the concen-
trationof furosemide); limits of detection andquantification
were 0.15 and 0.46 mmolL1, respectively. Teuto commercial
tablet samples were analyzed in order to evaluate recovery,
showing recoveries from 98 to 102%.
Fig. 4. Electrochemical impedance spectra for (*) blank, (~) 8, and (!) 16 mmol L1 furosemide spiked solutions at þ0.5, 0.75, 1.0 and
1.1 V vs. SCE.
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Experiments using square-wave voltammetry were also
carried out. Best conditions were found using 10 Hz
frequency and 5 mV potential increment, with 25 mV
amplitude, scanning from þ0.6 to þ1.2 V vs. SCE, the
oxidation peak appearing at þ0.96 V. The linear range was
from 3 to 9 mmol L1 (Ip (A)¼ 0.1 Cþ 1.5 107,R2¼ 0.988,
n¼ 6); limits of detection and quantifications of 0.96 and
3.2 mmol L1, respectively, were found. Recovery tests with
furosemide from Pharlab tablets led to results from 103 to
104%.
Careful examination of the results obtained suggests that
differential pulse voltammetry is probably the technique
which offers the best results in terms of linear range,
detection limit and recovery.
3.4. Statistical Evaluation and Comparison with the
Reference Method
In order to compare the applicability of the developed
methods, student t-paired tests were done, showing agree-
ment at the 95% confidence level for Furosix, Neosemid,
and Pharlab samples, and 99% confidence level for Teuto.
Results were also compared with those found using the
spectrophotometric reference method, reaching the same
conclusions concerning applicability to the analysis of
commercial samples.
4. Conclusions
A graphite-polyurethane composite electrode has been used
for voltammetric quantification of furosemide in commercial
samples without adsorption of furosemide or its oxidation
products. A possible mechanism for furosemide oxidation is
suggested. On the graphite-polyurethane electrode material
there is no analyte adsorption, shown by voltammetric
techniques and by electrochemical impedance, thus demon-
strating its viability for repetitive determinations without
electrode surface regeneration or renewal.
This new experimental procedure is faster and more
reproducible than previously-developed electrochemical
detection methods. It can be expected that similar advan-
tages of avoiding adsorption by using this composite
electrode will be found for other pharmaceutical com-
pounds, thus enhancing the applicability of such electro-
analytical procedures.
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